Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $16.00
Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $16.00
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) had its target price reduced by analysts at The Goldman Sachs Group from $18.00 to $16.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. The Goldman Sachs Group's price objective indicates a potential upside of 14.04% from the stock's current price.
据Benzinga报道,在周二发布给投资者的一份报告中,高盛的分析师将马拉维生命科学(纳斯达克:MRVI-GET评级)的目标价从18.00美元下调至16.00美元。该券商目前对该股的评级为“买入”。高盛的目标价表明,该股目前的价格可能上涨14.04%。
MRVI has been the topic of a number of other reports. Royal Bank of Canada assumed coverage on shares of Maravai LifeSciences in a research report on Tuesday, December 6th. They set an "outperform" rating and a $22.00 target price on the stock. Morgan Stanley lowered their target price on Maravai LifeSciences from $35.00 to $32.00 and set an "overweight" rating for the company in a research note on Friday, November 4th. Robert W. Baird cut their price target on Maravai LifeSciences from $34.00 to $25.00 in a research note on Thursday, November 3rd. UBS Group lowered Maravai LifeSciences from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $20.00 to $16.00 in a research report on Thursday, January 5th. Finally, Bank of America downgraded shares of Maravai LifeSciences from a "buy" rating to a "neutral" rating and cut their target price for the company from $32.00 to $17.00 in a research report on Thursday, November 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $23.00.
MRVI一直是其他一些报告的主题。加拿大皇家银行在12月6日(星期二)的一份研究报告中对马拉威生命科学的股票进行了报道。他们为该股设定了“跑赢大盘”的评级和22.00美元的目标价。11月4日,周五,摩根士丹利在一份研究报告中将马拉维生命科学的目标价从35.00美元下调至32.00美元,并为该公司设定了“增持”评级。11月3日星期四,罗伯特·W·贝尔德在一份研究报告中将Maravai LifeSciences的目标价从34.00美元下调至25.00美元。在1月5日周四的一份研究报告中,瑞银集团将Maravai LifeSciences的评级从买入下调至中性,并将该股的目标价从20.00美元下调至16.00美元。最后,在11月3日周四的一份研究报告中,美国银行将Maravai LifeSciences的股票评级从买入下调至中性,并将该公司的目标价从32.00美元下调至17.00美元。两名分析师对该股的评级为持有,六名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该公司目前的平均评级为“中等买入”,共识目标价为23.00美元。
Maravai LifeSciences Stock Up 1.9 %
Maravai LifeSciences股价上涨1.9%
Shares of NASDAQ MRVI opened at $14.03 on Tuesday. Maravai LifeSciences has a 52-week low of $12.16 and a 52-week high of $41.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 6.68 and a current ratio of 7.22. The business has a fifty day moving average of $14.06 and a two-hundred day moving average of $19.80. The stock has a market cap of $3.58 billion, a PE ratio of 8.03 and a beta of -0.25.
周二,新浪纳斯达克MRVI的股价开盘报14.03美元。Maravai LifeSciences的52周低点为12.16美元,52周高位为41.82美元。该公司的负债权益比率为0.62,速动比率为6.68,流动比率为7.22。该业务的50日移动均线切入位为14.06美元,200日移动均线切入位为19.80美元。该股市值为35.8亿美元,市盈率为8.03倍,贝塔系数为-0.25。
Institutional Investors Weigh In On Maravai LifeSciences
机构投资者参与Maravai LifeSciences
Several large investors have recently bought and sold shares of MRVI. Massachusetts Financial Services Co. MA grew its holdings in shares of Maravai LifeSciences by 41.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 12,691,171 shares of the company's stock valued at $360,556,000 after buying an additional 3,726,068 shares during the period. Thrivent Financial for Lutherans bought a new stake in shares of Maravai LifeSciences in the third quarter worth about $65,350,000. Marshall Wace LLP lifted its holdings in shares of Maravai LifeSciences by 285.8% during the 3rd quarter. Marshall Wace LLP now owns 2,077,036 shares of the company's stock valued at $53,030,000 after purchasing an additional 1,538,680 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Maravai LifeSciences by 105.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,875,000 shares of the company's stock valued at $53,269,000 after purchasing an additional 961,800 shares during the period. Finally, Artemis Investment Management LLP increased its stake in Maravai LifeSciences by 69.9% during the 2nd quarter. Artemis Investment Management LLP now owns 2,234,566 shares of the company's stock worth $63,590,000 after purchasing an additional 918,958 shares in the last quarter. Institutional investors own 48.67% of the company's stock.
几家大型投资者最近买卖了MRVI的股票。今年第二季度,马云持有的Maravai LifeSciences股票增加了41.6%。马云目前持有该公司12,691,171股股票,价值360,556,000美元,在此期间又购买了3,726,068股。Thrient Financial for Lutherans在第三季度购买了Maravai LifeSciences的新股份,价值约65,350,000美元。马歇尔·华斯有限责任公司在第三季度增持了Maravai LifeSciences的股票,增幅为285.8%。马歇尔·华斯有限责任公司在上个季度额外购买了1,538,680股后,现在拥有2,077,036股该公司股票,价值53,030,000美元。复兴科技有限责任公司在第二季度将其在马拉威生命科学公司的股票持有量增加了105.3%。复兴技术有限责任公司现在拥有1,875,000股该公司的股票,价值53,269,000美元,在此期间又购买了961,800股。最后,Artemis Investment Management LLP在第二季度增持了Maravai LifeSciences 69.9%的股份。Artemis Investment Management LLP现在拥有该公司2,234,566股股票,价值63,590,000美元,上个季度又购买了918,958股。机构投资者持有该公司48.67%的股份。
Maravai LifeSciences Company Profile
Maravai LifeSciences公司简介
(Get Rating)
(获取评级)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai LifeSciences控股公司是一家生命科学公司,提供能够在美国和国际上开发药物疗法、诊断、新型疫苗和支持人类疾病研究的产品。该公司的产品涉及生物制药开发的关键阶段,包括用于诊断和治疗应用的核酸、在生物制药产品生产过程中检测杂质的基于抗体的产品,以及检测各种组织中蛋白质表达的产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 免费获取StockNews.com关于Maravai LifeSciences(MRVI)的研究报告
- 宝洁收益:一场值得冒险的赌博
- 股市下滑,经济报告为经济描绘黯淡图景
- 如新控股股票与沃伦·巴菲特有什么关系?
- J.B.亨特买房,物流公司成为焦点
- 英特尔股票是否即将突破?
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Maravai生命科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Maravai LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。